Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women

Epilepsia

Volumn 40, Issue 6, 1999, Pages 783-787

  Fattore, C ^a   Cipolla, G ^a   Gatti, G ^a   Limido, G L ^b   Sturm, Y ^c   Bernasconi, C ^d   Perucca, E ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Novartis Medical Department (CNS)   (Italy)

^c NOVARTIS PHARMA AG   (Switzerland)

^d IPAS SA   (Switzerland)

Author keywords

Drug interaction; Enzyme induction; Ethinylestradiol; Levonorgestrel; Oral contraceptives; Oxcarbazepine

Indexed keywords

CARBAMAZEPINE; CITALOPRAM; CYTOCHROME P450 ISOENZYME; DEXTROPROPOXYPHENE; ERYTHROMYCIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; NEUROLEPTIC AGENT; OXCARBAZEPINE; VALPROIC ACID; VERAPAMIL; VILOXAZINE; WARFARIN;

ADULT; ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG METABOLISM; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; FEMALE; GESTAGEN BLOOD LEVEL; HUMAN; MENSTRUAL CYCLE; METABOLIC ACTIVATION; NORMAL HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CARBAMAZEPINE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; ENZYME INDUCTION; ETHINYL ESTRADIOL; FEMALE; HALF-LIFE; HUMANS; LEVONORGESTREL; OXIDOREDUCTASES, N-DEMETHYLATING; PLACEBOS;

EID: 0033052684     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00779.x     Document Type: Article

References (29)

1. Faigle JW, Menge GP. Pharmacokinetic and metabolic features of oxcarbazepine and their clinical significance: comparison with carbamazepine. Int Clin Psychopharmacol 1990;5:73-82.
2. Grant SM, Faulds D. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992;43:873-88.
3. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35(suppl 3): 10-3.
4. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical significance. Epilepsia 1994;35 (suppl 3):14-9.
5. Tartara A, Galimberti CA, Manni R, et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Phannacol 1993;36:366-8.
6. Keranen T, Jolkkonen J, Klosterkov Jensen P, Menge GP, Andersson P. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 1992;86:120-3.
7. Mogensen PH, Jorgensen L, Boas J, et al. Effects of dextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites. Acta Neurol Scand 1992;85:14-7.
8. Kramer G, Tettenborn B, Flesch G. Oxcarbazepine-verapamil drug interaction in healthy volunteers. Epilepsia 1991;32(suppl 1):70-1.
9. Pisani F, Fazio A, Oteri G, Artesi C, Xiao B, Perucca E, Di Perri R. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Acta Neurol Scand 1994;90:130-2.
10. Larkin JO, McKee PJ, Forrest G, et al. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991;31:65-71.
11. Houtkooper MA, Lammertsma A, Meijer JWA, et al. Oxcarbazepine (CGP47680): a possible alternative to carbamazepine? Epilepsia 1987;28:693-8.
12. Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. Psychopharmacology 1994;116:115-6.
13. Leinenen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels: a report on two cases. Pharmacopsychiatry 1996;29:156-8.
14. Kramer G, Tettenborn B, Klosterkov Jensen P, Menge GP, Stoll KD. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992;33:1145-8.
15. Perucca E, Richens A. Biotransformation. In: Levy RH, Mattson RH, Meldrum B, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:31-50.
16. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 1996;31:198-214.
17. Brockmoller J, Roots I. Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet 1994;27:216-48.
18. Patsalos PN, Zakrzewska JM, Elyas AA. Dose-dependent enzyme induction by oxcarbazepine? Eur J Clin Pharmacol 1990;39: 187-8.
19. Zaccara G, Gangemi PF, Bendoni L, et al. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit 1993;15:39-42.
20. Capewell S, Freestone S, Critchley JAJH, Pottage A, Prescott LF. Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet 1988;2:480-2.
21. Klosterkov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992;33:1149-52.
22. Guengerich FP. Oxidation of 17β-ethinyloestradiol by human liver cytochrome P450. Mol Pharmacol 1988;33:500-8.
23. Back DJ, Orme MLE. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18:472-84.
24. Fotherby K. Pharmacokinetics of gestagens: some problems. Am J Obstet Gynecol 1990;163:323-8.
25. Fotherby K. Levonorgestrel: clinical pharmacokinetics. Clin Pharmacokinet 1995;28:203-15.
26. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
27. Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990;30:892-6.
28. Back DJ, Bates M, Bowden A, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 1980;22:495-503.
29. Sonnen AEH. Oxcarbazepine and oral contraceptives. Acta Neurol Scand 1990;82(suppl 133):37.